会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • MOTOR VENTILATION STRUCTURE AND MOTOR
    • WO2018196003A1
    • 2018-11-01
    • PCT/CN2017/082616
    • 2017-04-28
    • SIEMENS AKTIENGESELLSCHAFTJIANG, Zhiwei
    • JIANG, Zhiwei
    • H02K9/08F24F11/00H02K5/20F04D25/08F04D29/30
    • H02K5/20H02K9/08
    • The motor ventilation structure (20) is disposed inside a housing (31) of the motor (30), and the motor (30) is provided with a drive end (301) and a non-drive end (302) opposite to the drive end. The motor ventilation structure (20) includes: a first air baffle (21), located on the drive end (301), where the first air baffle (21) is spaced from a side wall of the housing of the motor (30), so as to form an accommodation space (210) with the housing (31); a ventilation pipe (22), fixed on the first air baffle (21), where the ventilation pipe (22) extends from the non-drive end (302) of the motor (30) to the drive end (301) of the motor (30) and is in communication with the accommodation space (210); and a double-suction fan (23), fixedly sleeved on a rotation shaft (32) of the motor (30) and disposed on one side, close to the non-drive end (302), of the first air baffle (21), where the double-suction fan (23) is configured to extract air from the non-drive end (302) to the drive end (301), and extract air in the accommodation space (210) and air for axial-radial cooling out of the housing (31) of the motor (30). The motor ventilation structure (20) and the motor (30) may ensure that a bearing of the drive end of the motor (30) has an appropriate temperature, and may achieve relatively high heat dissipation efficiency.
    • 9. 发明申请
    • PHARMACEUTICAL COMPOSITIONS CONTAINING BETA-LAPACHONE, OR DERIVATIVES OR ANALOGS THEREOF, AND METHODS OF USING SAME
    • 含有β-Lapapone或其衍生物或类似物的药物组合物及使用该组合物的方法
    • WO2003011224A2
    • 2003-02-13
    • PCT/US2002/024262
    • 2002-07-31
    • CYCLIS PHARMACEUTICALS, INC.JIANG, ZhiweiREDDY, Dasharatha, G.
    • JIANG, ZhiweiREDDY, Dasharatha, G.
    • A61K
    • A61K9/0019A61K31/337A61K31/352A61K47/10A61K47/24A61K47/32Y10S514/937Y10S514/941Y10S514/97A61K2300/00
    • Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-β-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy. A formulation of Beta-lapachone or a derivative or analog thereof, complexed with a pharmaceutically acceptable solubilizing carrier molecule, wherein the complex can be freeze-dried and when subsequently reconstituted in aqueous solution is substantially soluble is also disclosed. Emulsions of Beta-Lapachone in a pharmaceutically acceptable fat emulsion vehicle are also provided. Also disclosed are methods for treating cancer by administering to a patient the novel pharmaceutical compositions and formulations. Pharmaceutical kits are also provided.
    • 在大多数药学上可接受的溶剂中难以溶解的β-拉帕醌已经显示出对人癌细胞系具有显着的抗肿瘤活性。 本发明通过教导包含治疗有效量的β-拉帕醌或其衍生物或类似物以及药学上可接受的增溶载体分子的新颖药物组合物来克服这一显着限制,所述载体分子可以在水溶性载体分子如羟丙基 - β-环糊精或基于油的增溶载体分子,用于增强β-拉帕醌在水溶液中的溶解度。 β-拉帕醌或其衍生物或类似物的治疗有效量可以与药学上可接受的增溶载体分子在水溶液中复合。 新型药物组合物可以与第二种抗癌剂一起给药或与放射疗法联合给药。 与药学上可接受的增溶载体分子络合的β-拉帕醌或其衍生物或类似物的制剂,其中该络合物可以冷冻干燥,并且随后在水溶液中重构时基本上可溶。 还提供了β-拉帕醌在药学上可接受的脂肪乳剂载体中的乳剂。 还公开了通过向患者施用新药物组合物和制剂来治疗癌症的方法。 还提供药品包。